Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Phase 2 Completed 28 enrolled University of Alabama at Birmingham Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine pathological response to a maximum of 18 weeks of neoadjuvant therapy using a combination of letrozole and Bevacizumab in post-menopausal women with pathologically confirmed invasive ductal cancer or invasive lobular cancer of the breast whose tumors are hormone positive.

Timeline

Start: 2005-06
Primary completion: 2006-11
Completion: 2006-11

Publications

Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast Cancer Res. 2020 Feb 18;22(1):22. doi: 10.1186/s13058-020-01258-x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Letrozole	Other / unclassified	2.5 mg	—

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Summary

Timeline

Publications

Drugs

Indications